Estrella Immunopharma, Inc. (ESLAW) Stock Price & Analysis
Estrella Immunopharma, Inc. (ESLAW) closed at USD 0.05 on Tuesday, October 6, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.05; the Oct 6, 2026 session ranged USD 0.05–0.05 on volume of 0 shares. Market capitalization is —, with a 52-week range of USD 0.05–0.05 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:10 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ESLAW.md
Key facts (ESLAW)
- Analysts: None.
Analysts (ESLAW)
Consensus None.
Key Statistics (as of October 16, 2026 at 05:10 UTC)
| Price | USD 0.05 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.05 |
| Open | USD 0.11 |
| Day Range | USD 0.05 – 0.05 |
| 52-Week Range | USD 0.05 – 0.05 |
| Volume | 0 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (ESLAW)
Wall Street analysts rate ESLAW "None", per Nexqual as of October 16, 2026 at 05:10 UTC.
| Consensus Rating | None |
|---|
Earnings (ESLAW)
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Financials & Fundamentals (ESLAW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.28 |
| Total Cash | $2.48M |
| Total Debt | $22,000 |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Financial Health Score (ESLAW)
Nexqual rates Estrella Immunopharma, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $2M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$1M (TTM) |
| Efficiency | Mixed — No data |
Ownership (ESLAW)
| Float | 9.10M |
|---|
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Leadership (ESLAW)
Estrella Immunopharma, Inc. is led by Cheng Liu (age 55), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:10 UTC.
| CEO, President & Director | Cheng Liu (age 55) |
|---|---|
| Chief Financial Officer | Jiandong Xu (age 51) |
Major Backers & Investors (ESLAW)
Notable institutional backers of Estrella Immunopharma, Inc. include Boothbay Fund Management, LLC, Shaw D.E. & Co., Inc., SkyView Investment Advisors, LLC, according to Nexqual as of October 16, 2026 at 05:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Boothbay Fund Management, LLC | 8.57% |
| Shaw D.E. & Co., Inc. | 3.95% |
| SkyView Investment Advisors, LLC | 2.82% |
| Yakira Capital Management, Inc. | 2.09% |
| Whitebox Advisors, LLC | 1.91% |
| Clear Street Group Inc. | 1.54% |
| Toronto Dominion Bank | 0.98% |
| Robertson Stephens Wealth Management, LLC | 0.54% |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorpor | USD 508.75 | ▲ 4.85% |
| MRNA | Moderna, Inc. | USD 236.5 | ▲ 9.36% |
| REGN | Regeneron Pharmaceuticals, Inc. | USD 796.34 | ▲ 5.74% |
| ARGX | argenx SE | USD 846.27 | ▲ 5.44% |
| ONC | BeOne Medicines Ltd. | USD 374.08 | ▲ 7.16% |
| RVMD | Revolution Medicines, Inc. | USD 189.26 | ▲ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:10 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt